Strategic partnership announced: Kreussler and STD are working together to create synergies in varicose vein treatment.

PARIS, 14 DECEMBER 2023 | Kreussler Pharma – During the Kreussler-sponsored symposium at the 81st Annual Congress of the French Society of Phlebology, Chemische Fabrik Kreussler & Co. GmbH and STD Pharmaceutical Products Ltd. announced their collaboration on the global production, marketing and distribution of Fibrovein.

“STD had been looking for a strategic partner for some time to help leverage synergies in the production and worldwide marketing of Fibrovein. In the wake of Brexit, we decided to move Fibrovein production to the EU and are pleased to partner with Kreussler, a family business similar to ours, known to us for many years and sharing our values and our vision for advancing sclerotherapy,” said Bruce Gardiner, Managing Director of STD.

“As a globally recognised leader in sclerotherapy and the owner of Aethoxysklerol, this collaboration represents an important opportunity for Kreussler to reinforce and further advance the role of sclerotherapy compared with alternative treatments for varicose veins. We are pleased to now offer our customers the two most widely used sclerosing agents worldwide. “With our expertise, infrastructure and international network, we have the capacity to make full use of production and marketing synergies for Aethoxysklerol and Fibrovein,” said Dr Stephan Travers, co-owner and managing director of Kreussler.

Sclerotherapy is a highly effective, FDA-approved outpatient treatment for varicose veins with an excellent safety profile. It does not require anaesthesia and is recognised as one of the most cost-effective approaches. To achieve the highest level of treatment competence, Kreussler founded the Kreussler International School of Sclerotherapy (KISS), which serves as a platform for training prospective sclerotherapists and delivering international standards in diagnostics and sclerotherapy technique. The partnership with STD now allows Kreussler to incorporate Fibrovein into the training programme.